Allergan faces law suit alleging payment of kickbacks to optometrists to prescribe Restasis

14 February 2014

US drugmaker Allergan (NYSE: AGN) is the subject of legal action after allegations that it paid kickbacks to induce prescriptions of its eye care drugs.

The drugmaker is facing a law suit in the federal court in Philadelphia, filed by Pietragallo Gordon Alfano Bosick & Raspanti and Goldberg Kohn on behalf of two Philadelphia-area ophthalmologists. On behalf of the federal and state governments, the complaint seeks to recover damages and penalties under federal and state False Claims Acts.

The law suit alleges that Allergan provided illegal inducements to eye care professionals throughout the USA, including business consulting services through its team of Eye Care Business Advisors.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK